View in EDS HTML Full Text PDF Full Text

Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants.

Saved in:
Bibliographic Details
Title: Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants.
Authors: Goncalves MB; Neuroscience Drug Discovery Unit, The Wolfson Centre for Age-Related Diseases, King's College London, Guy's Campus, London, UK., Mant T; NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, Guy's and St Thomas' NHS Foundation Trust, London, UK., Täubel J; Richmond Pharmacology Limited, London, UK., Clarke E; Neuroscience Drug Discovery Unit, The Wolfson Centre for Age-Related Diseases, King's College London, Guy's Campus, London, UK., Hassanin H; Surrey Clinical Research Centre, University of Surrey, Surrey, UK., Bendel D; Surrey Clinical Research Centre, University of Surrey, Surrey, UK., Fok H; NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, Guy's and St Thomas' NHS Foundation Trust, London, UK., Posner J; Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science, King's College London, London, UK., Holmes J; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Mander AP; Centre for Trials Research, Cardiff University, Cardiff, UK., Corcoran JPT; Neuroscience Drug Discovery Unit, The Wolfson Centre for Age-Related Diseases, King's College London, Guy's Campus, London, UK.
Source: British journal of clinical pharmacology [Br J Clin Pharmacol] 2023 Dec; Vol. 89 (12), pp. 3573-3583. Date of Electronic Publication: 2023 Aug 09.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37452623
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Goncalves+MB%22">Goncalves MB</searchLink>; Neuroscience Drug Discovery Unit, The Wolfson Centre for Age-Related Diseases, King's College London, Guy's Campus, London, UK.<br /><searchLink fieldCode="AU" term="%22Mant+T%22">Mant T</searchLink>; NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, Guy's and St Thomas' NHS Foundation Trust, London, UK.<br /><searchLink fieldCode="AU" term="%22Täubel+J%22">Täubel J</searchLink>; Richmond Pharmacology Limited, London, UK.<br /><searchLink fieldCode="AU" term="%22Clarke+E%22">Clarke E</searchLink>; Neuroscience Drug Discovery Unit, The Wolfson Centre for Age-Related Diseases, King's College London, Guy's Campus, London, UK.<br /><searchLink fieldCode="AU" term="%22Hassanin+H%22">Hassanin H</searchLink>; Surrey Clinical Research Centre, University of Surrey, Surrey, UK.<br /><searchLink fieldCode="AU" term="%22Bendel+D%22">Bendel D</searchLink>; Surrey Clinical Research Centre, University of Surrey, Surrey, UK.<br /><searchLink fieldCode="AU" term="%22Fok+H%22">Fok H</searchLink>; NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, Guy's and St Thomas' NHS Foundation Trust, London, UK.<br /><searchLink fieldCode="AU" term="%22Posner+J%22">Posner J</searchLink>; Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science, King's College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Holmes+J%22">Holmes J</searchLink>; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Mander+AP%22">Mander AP</searchLink>; Centre for Trials Research, Cardiff University, Cardiff, UK.<br /><searchLink fieldCode="AU" term="%22Corcoran+JPT%22">Corcoran JPT</searchLink>; Neuroscience Drug Discovery Unit, The Wolfson Centre for Age-Related Diseases, King's College London, Guy's Campus, London, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227503323%22">British journal of clinical pharmacology</searchLink> [Br J Clin Pharmacol] 2023 Dec; Vol. 89 (12), pp. 3573-3583. <i>Date of Electronic Publication: </i>2023 Aug 09.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>7503323 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1365-2125 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203065251%22">03065251 </searchLink><i>NLM ISO Abbreviation: </i>Br J Clin Pharmacol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37452623
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/bcp.15854
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3573
    Titles:
      – TitleFull: Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Goncalves MB
      – PersonEntity:
          Name:
            NameFull: Mant T
      – PersonEntity:
          Name:
            NameFull: Täubel J
      – PersonEntity:
          Name:
            NameFull: Clarke E
      – PersonEntity:
          Name:
            NameFull: Hassanin H
      – PersonEntity:
          Name:
            NameFull: Bendel D
      – PersonEntity:
          Name:
            NameFull: Fok H
      – PersonEntity:
          Name:
            NameFull: Posner J
      – PersonEntity:
          Name:
            NameFull: Holmes J
      – PersonEntity:
          Name:
            NameFull: Mander AP
      – PersonEntity:
          Name:
            NameFull: Corcoran JPT
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2023 Dec
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1365-2125
          Numbering:
            – Type: volume
              Value: 89
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: British journal of clinical pharmacology
              Type: main
ResultId 1